Leukemia
FDA investigates potential increased death risk with lymphoma therapy Ukoniq
The FDA is investigating a possible increased mortality risk with umbralisib, approved in the United States for treatment of two types of lymphoma.
Chemotherapy-free regimen benefits children with acute promyelocytic leukemia
Children with acute promyelocytic leukemia achieved survival benefit with an all-trans retinoic acid and arsenic trioxide chemotherapy-free regimen, according to study results published in JAMA Oncology.
Out-of-spec CAR-T appears safe, effective for younger patients with ALL
B-cell acute lymphoblastic leukemia is the most common type of cancer among children.
FDA grants orphan drug designation to CAR T-cell therapy for advanced ALL
The FDA granted orphan drug designation to CNCT19, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory acute lymphoblastic leukemia.
Gilead withdraws Zydelig indication for lymphoma, leukemia subtypes
Gilead Sciences has decided to voluntarily withdraw its accelerated approval of idelalisib for two blood cancer indications.
Survival rate rises steadily among patients with relapsed ALL after stem cell transplant
The 2-year OS rate nearly doubled during the past 2 decades among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation, according to study results.
Many hospitals lack key treatment for acute promyelocytic leukemia
Less than one-third of hospitals had access to the life-saving agent all-trans retinoic acid for patients with acute promyelocytic leukemia, according to study results published in Journal of the National Comprehensive Cancer Network.
FDA grants breakthrough device designation to BNT200 for anxiety in acute myeloid leukemia
The FDA granted breakthrough device designation to BNT200.
Naive T-cell depletion approach results in lower rates of chronic GVHD after transplant
Depletion of naive T cells from peripheral blood stem cell grafts resulted in very low incidence of severe acute and any graft-versus-host disease in three phase 2 clinical trials, according to a study in Journal of Clinical Oncology.
Patients with acute myeloid leukemia report ongoing symptoms, impacts after transplant
Individuals with acute myeloid leukemia in remission after hematopoietic stem cell transplantation reported ongoing symptoms and impacts in the post-transplant period, according to research presented at ASH Annual Meeting and Exposition.